The Effect of Depressive Disorders on the Autonomous Choice to Forgo Medical Treatment (Doctoral Dissertation, Duquesne University)

Total Page:16

File Type:pdf, Size:1020Kb

The Effect of Depressive Disorders on the Autonomous Choice to Forgo Medical Treatment (Doctoral Dissertation, Duquesne University) Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Spring 2006 Depression, Volition, and Death: The ffecE t of Depressive Disorders on the Autonomous Choice to Forgo Medical Treatment Matthew utkB us Follow this and additional works at: https://dsc.duq.edu/etd Recommended Citation Butkus, M. (2006). Depression, Volition, and Death: The Effect of Depressive Disorders on the Autonomous Choice to Forgo Medical Treatment (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/370 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. DEPRESSION, VOLITION, AND DEATH: THE EFFECTS OF DEPRESSIVE DISORDERS ON THE AUTONOMOUS CHOICE TO FORGO MEDICAL TREATMENT A Dissertation Presented to the Faculty of the McAnulty College and Graduate School of Liberal Arts Duquesne University in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Matthew Allen Butkus, MA DEPRESSION, VOLITION, AND DEATH: THE EFFECTS OF DEPRESSIVE DISORDERS ON THE AUTONOMOUS CHOICE TO FORGO MEDICAL TREATMENT TABLE OF CONTENTS ACKNOWLEDGEMENTS i GENERAL INTRODUCTION iii CHAPTER ONE: We’re Not as Free as We Think We Are – Reductionist 1 and Determinist Ontologies in Human Cognition Reductionism 2 Definitions 5 Concepts/Types of Reduction 9 Challenges to Reductionism 24 The Shift Towards Determinism 44 Determinism 45 Key Definitions in the Determinism Debate 57 Concepts in the Determinism Debate 62 Indeterminism 63 Determinism 79 Libertarianism, Compatibilism, and Challenges to Both 86 Alternative Theories in the Determinism Debate 90 The Resulting Philosophical Model and the Consequences for Cognition 96 CHAPTER TWO: “Rationality” Isn’t So Rational – Automaticity, 98 Backstage Cognition, and Cognitive Heuristics in “Rational” Thought Backstage Cognition, Mental Spaces, and Automaticity 100 Automaticity 103 Conceptual Blending and Mental Spaces 112 Cognitive Heuristics 118 Definitions 126 Specific Heuristics 128 Challenges 142 Complementary/Supplementary Theories 151 Affect and Rationality 161 CHAPTER THREE: Hidden Comorbidities – Diagnostic Criteria of Depressive 173 Disorders and Their Prevalence in Five Common Medical Conditions Depressive Disorders 180 Epidemiology of Affective Disorders 181 Etiologies 199 Treatment 217 Multiple Sclerosis 226 Epidemiology 227 Course of the Illness 227 Rates of Depression 228 Treatment Options 230 Parkinson’s Disease 231 Epidemiology 232 Course of the Illness 233 Rates of Depression 234 Treatment 236 Dementia 239 Epidemiology 243 Course of the Illness 254 Treatment 257 Comorbid Depression 258 Stroke 260 Epidemiology 265 Course of the Illness 266 Depression and Cognitive Dysfunction 268 Treatment 278 Cancer 280 Epidemiology 285 Comorbid Depression 286 Treatment 294 Conclusion 301 CHAPTER FOUR: Of Icebergs and Autonomy – Cognitive Distortions and the 303 Fallacy of Homuncular Autonomy Depressive Cognition 303 Cognitive Distortion and Beck’s Model 304 The Theory of Depressive Realism 314 Which is Right? 335 Autonomy 336 Critiques of Autonomy 339 Homuncular Autonomy Models (Veatch; Faden and Beauchamp; Beauchamp 341 and Childress) Cognitive Autonomy Models (Redelmeier, et al.; Grisso and Appelbaum; Katz; 367 Anderson and Lux) Conclusion 392 Foundational Criteria of Autonomy 393 Medical Criteria of Autonomy 396 Psychiatric Criteria of Autonomy 398 Psychosocial Criteria of Autonomy 398 CHAPTER FIVE: Faces of Choice and Volition – A Case Metric Approach to 401 Assessing Decision-Making Capacity Diagnostic Psychometrics 401 Case Metric 412 Alice 414 Bill 421 Catherine 429 David 437 Eugenia 444 Frank 452 Georgette 458 Harry 466 Irene 473 CONCLUSION 481 APPENDIX: Psychometric Scales 484 BIBLIOGRAPHY 485 ACKNOWLEDGEMENTS First, I would like to thank Adam J. Butkus, Lynne A. Weber, Janet Popeleski, and Douglas J. Sterling, my parents, for everything they have done to help me to get to this point in my life – I cannot list the ways in which I have depended upon them without adding an additional volume to this work. I would like to thank the faculty and clinical staff of Duquesne University, the University of Pittsburgh, St. Francis Health System, and Western Psychiatric Institute and Clinic for the inspiration, knowledge, and resources needed to bring this to fruition. I would like to thank the psychiatric and nursing staff at Mercy Hospital North Shore Campus for two years of clinical experience, allowing me to appreciate the continuity of care issues in clinical psychiatry. I would like to thank David Kelly, Aaron Mackler, and Bryan Chambliss for their patience and direction in bringing this dissertation to fruition. I would like to thank William Klein for allowing me to bounce ideas off of him prior to writing, as well as for exposing me to elements of cognitive psychology I had not read or researched that were directly germane to the discussion contained within. I would like to thank Barbara Kucinski for exposing me to and clarifying elements in biopsychology and psychoneuroimmunology of which I had only surface familiarity. I would like to thank Matthew Bundick for guidance in concretizing my hitherto ad hoc education in psychology. I would like to thank Richard and Jennifer Schiavoni and Matthew Gourley for too many late evenings and dinners, which prevented my mental breakdown. Finally, I would like to thank Raymond Klavon, who is, without a doubt, the most patient and kindest person a graduate student could ever hope to have as a landlord. i In doubt his Mind or Body to prefer, Born but to die, and reas’ning but to err; Alike in ignorance, his reason such, Whether he thinks to little, or too much: Chaos of Thought and Passion, all confus’d; Still by himself abus’d, or disabus’d; Created half to rise, and half to fall; Great lord of all things, yet a prey to all; Sole judge of Truth, in endless error hurl’d: The glory, jest, and riddle of the world! -Alexander Pope An Essay on Man It is a wonderful feeling to recognize the unity of a complex of phenomena that to direct observation appear to be quite separate things. -Albert Einstein Letter to Marcel Grossman The mind is inherently embodied. Thought is mostly unconscious. Abstract concepts are largely metaphorical. These are three major findings of cognitive science. More than two millennia of a priori philosophical speculation about these aspects of reason are over. Because of these discoveries, philosophy can never be the same again… Philosophical sophistication is necessary if we are to keep science honest. Science cannot maintain a self-critical stance without a serious familiarity with philosophy and alternative philosophies. Scientists need to be aware of how hidden a priori philosophical assumptions can determine their scientific results. This is an important lesson to be drawn from the history of first-generation cognitive science, where we saw how much analytic philosophy intruded into the initial conception of what cognitive science was to be. On the other hand, philosophy, if it is to be responsible, cannot simply spin out theories of mind, language, and other aspects of human life without seriously encountering and understanding the massive body of relevant ongoing scientific research. Otherwise, philosophy is just storytelling, a fabrication of narratives ungrounded in the realities of human embodiment and cognition. If we are to know ourselves, philosophy needs to maintain an ongoing dialogue with the sciences of mind. - George Lakoff and Mark Johnson Philosophy in the Flesh GENERAL INTRODUCTION The Nature and Purpose of this Dissertation Since its inception, medical ethics has concerned itself with balancing several key concepts – the patient’s best interest, both psychosocial and medical; the patient’s legal rights and autonomy; the authenticity of the patient’s decision, i.e., narrative concerns that the patient’s choice be reflective of her values, etc. As is the case with any pluralistic system, these concepts are complementary at times and conflicting at times. Significant efforts to determine just how to proceed in any given case result, both in academic circles, in which theories clash and value structures rise and fall, as well as in clinical cases, in which academic language gives way to clinical context and lives hang in the balance. These values have been stressed in different manners at different times – before the advent of medical ethics as a field in itself, the physician-patient relationship was defined in paternalistic terms. The physician, being the source of medical knowledge and prognostic wisdom, had an air of authority which one dared not question. Decisions were top-down, in the manner of a general commanding his soldiers, and were rarely questioned. While the patient’s concerns were counted, what was in their medical best interest carried the day. This perspective evolved over time, and a different model of physician-patient interaction emerged. Patient advocacy found legal and philosophical recourse in autonomy models which stressed the ability of a patient to choose the treatment she wanted, and patients’ rights became more than an ephemeral concept. Decisions proceeded on egalitarian terms, in which the patient and the treatment team reached an accord – the patient’s medical best interest was now simply one factor
Recommended publications
  • MEMORY BIASES and DEPRESSIVE REALISM a Dissertation Submitted
    MEMORY BIASES AND DEPRESSIVE REALISM A dissertation submitted to Kent State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Michael T. Moore August 2009 Dissertation written by Michael T. Moore B.A., State University of New York at Stony Brook, 2000 M.A., Kent State University, 2005 Ph.D., Kent State University, 2009 Approved by __________________________________, David M. Fresco, Ph.D., Co-Chair, Doctoral Dissertation Committee __________________________________, T. John Akamatsu, Ph.D., Co-Chair, Doctoral Dissertation Committee __________________________________, Maria S. Zaragoza, Ph. D., Member, Doctoral Dissertation Committee __________________________________, Barbara L. Drew, Ph.D., R.N., Member, Doctoral Dissertation Committee __________________________________, Richard Adams, Ph. D., College of Arts & Sciences Graduate Faculty Representative Accepted by __________________________________, Doug L. Delahanty, Ph.D., Interim Chair, Department of Psychology __________________________________, Timothy S. Moerland, Ph.D., Dean, College of Arts and Sciences ii TABLE OF CONTENTS ACKNOWLEDGMENTS………………………………………………………...………………iv INTRODUCTION…………………………………………………………………………………1 Hypotheses……………………………………………………………………………….17 METHOD………………………………………………………………………………………...18 Participants and Procedure……………………………………………………………….18 Power Analysis…………………………………………………………………………..19 Measures…………………………………………………………………………………20 RESULTS………………………………………………………………………………………...26 DISCUSSION…………………………………………………………………………………….35
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • For Peer Review Only Journal: BMJ Open
    BMJ Open BMJ Open: first published as 10.1136/bmjopen-2016-012044 on 13 December 2016. Downloaded from Can commonly prescribed drugs be repurposed for the prevention or treatment of Alzheimer’s and other neurodegenerative diseases? Protocol for an observational cohort study in the UK Clinical Practice Research Datalink For peer review only Journal: BMJ Open Manuscript ID bmjopen-2016-012044 Article Type: Protocol Date Submitted by the Author: 23-Mar-2016 Complete List of Authors: Walker, Venexia; University of Bristol Davies, Neil; University of Bristol Jones, Tim; NIHR CLAHRC West Kehoe, Patrick; University of Bristol Martin, Richard; University of Bristol <b>Primary Subject Pharmacology and therapeutics Heading</b>: Secondary Subject Heading: Neurology, Epidemiology Dementia < NEUROLOGY, Parkinson-s disease < NEUROLOGY, Motor Keywords: neurone disease < NEUROLOGY, EPIDEMIOLOGY, THERAPEUTICS http://bmjopen.bmj.com/ on September 25, 2021 by guest. Protected copyright. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml Page 1 of 152 BMJ Open BMJ Open: first published as 10.1136/bmjopen-2016-012044 on 13 December 2016. Downloaded from 1 2 3 TITLE 4 5 Can commonly prescribed drugs be repurposed for the prevention or treatment of 6 Alzheimer’s and other neurodegenerative diseases? Protocol for an observational cohort 7 study in the UK Clinical Practice Research Datalink 8 9 10 CO-AUTHORS 11 1, 2 1, 2 3 4 1, 2 12 Venexia M Walker , Neil M Davies , Tim Jones , Patrick G Kehoe , Richard M Martin 13 14 1 School of Social
    [Show full text]
  • Deliverable 5.A Interim Report on the Study Results APPENDIX 2
    Deliverable 5.a Interim report on the study results APPENDIX 2: Algorithms used to identify study variables for service contract EMA/2011/38/CN ‐ PIOGLITAZONE November 28th 2012 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) APPENDIX 2. ALGORITHMS USED TO IDENTIFY STUDY VARIABLES Algorithms for AU Database DISEASE/CONDITION ICD-8 CODE (1977-1993) ICD-10 CODE (1994-) Diabetes type 2 250.00; 250.06; 250.07; 250.09 E11.0; E11.1; E11.9 Cancer of bladder 188 C67 Haematuria N/A R31 Haematuria, unspecified B18, K70.0–K70.3, K70.9, K71, K73, Mild hepatic impairment 571, 573.01, 573.04 K74, K76.0 Moderate to severe hepatic 070.00, 070.02, 070.04, 070.06, B15.0, B16.0, B16.2, B19.0, K70.4, impairment 070.08, 573.00, 456.00–456.09 K72, K76.6, I85 Acute myocardial infarction 410 I21-I23 Acute coronary syndrome 410, 413 I20-I24 Ischemic heart disease 410-414 I20-I25 427.09, 427.10, 427.11, 427.19, Congestive heart failure I50, I11.0, I13.0,I13.2 428.99, 782.49; Acute renal failure N/A N17 Diabetic coma N/A E10.0, E11.0, E12.0,E13.0, E14.0 Diabetic acidosis N/A E10.1, E11.1, E12.1,E13.1, E14.1 F10.1-F10.9, G31.2, G62.1, G72.1, Alcoholism 291, 303, 577.10, 571.09, 571.10 I42.6, K29.2, K86.0, Z72.1 Obesity 277.99 E65-E66 D5.a Interim report on the study results (Appendix 2) for Service Contract EMA/2011/38/CN PIOGLITAZONE Author(s): Vera Ehrenstein (AUH‐AS) Algorithms for defining acute events in Denmark, ICD-10 code Event ICD-10 code I21.x, I23.x http://apps.who.int/classifications/icd10/browse/2010/en#/I21
    [Show full text]
  • Guidance for the Format and Content of the Protocol of Non-Interventional
    PASS information Title Metformin use in renal impairment Protocol version identifier Version 2 Date of last version of 30 October 2013 protocol EU PAS register number Study not registered Active substance A10BA02 metformin Medicinal product Metformin Product reference N/A Procedure number N/A Marketing authorisation 1A Farma, Actavis, Aurobindo, Biochemie, Bluefish, holder(s) Hexal, Mylan, Orifarm, Pfizer, Sandoz, Stada, Teva Joint PASS No Research question and To assess the use and safety of metformin in patients objectives with and without renal insufficiency in current clinical practice in at least two EU Member States. Country(-ies) of study Denmark, United Kingdom Author Christian Fynbo Christiansen, MD, PhD Page 1/214 Marketing authorisation holder(s) Marketing authorisation N/A holder(s) MAH contact person N/A Page 2/214 1. Table of Contents PASS information .......................................................................................................... 1 Marketing authorisation holder(s) .................................................................................... 2 1. Table of Contents ...................................................................................................... 3 2. List of abbreviations ................................................................................................... 4 3. Responsible parties .................................................................................................... 5 4. Abstract ..................................................................................................................
    [Show full text]
  • To-Day's Drugs
    BRITISH 1073 APRIL 20, 1963 TO-DAY'S DRUGS MEDICAL JOURNAL who has made a reasonable recovery from a cerebro- Current Practice vascular episode should also have his blood-pressure lowered; there is evidence that the persistence of hypertension is an important factor in determining the TO-DAY'S DRUGS subsequent prognosis.3 Once a patient has definite evidence of renal failure IYPOTENSIVE DRUGS (Continued) with a persistently raised blood urea potent hypotensive drugs should be used with extreme caution. If given in GENERAL CONSIDERATIONS the usual dose their effects can be catastrophic; once this stage is reached they do not prolong life and are Choice of Patient only symptomatically helpful. At the present time our views about the selection of patients for treatment with hypotensive drugs are in a state of change. At first it was the practice to give Choice of Drug these drugs only to patients with malignant hypertension From what has already been said it will be apparent or those who had definite signs of hypertensive disease. that none of the hypotensive drugs at present available As newer and better hypotensive agents have come into is ideal. When the decision to treat a patient has been use the scope of treatment has been broadened and now made a balance must be struck between the need to there are some who believe that.a patient with a raised lower the blood-pressure and the frequency and severity blood-pressure should be treated even if he has no of the side-effects of the hypotensive drug. In the symptoms.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • The Tyranny of Optimism
    The Tyranny of Optimism C. W. Von Bergen Southeastern Oklahoma State University [email protected] Diane Bandow Troy University [email protected] ABSTRACT America culture emphasizes upbeat thinking, cheerfulness, optimism, and other manifestations of positive affect in its aphorisms, songs, religion, books and magazines, medicine, business, and psychology. This has led to the often unchallenged idea that positive thinking is always a good thing. This belief has caused the power that negative thinking and affect hold, in terms of realistic appraisals of the self and the world, to be not only underestimated, but often shunned as well. It is dangerous, however, to lose sight of unpleasant realities. The downfall of losing sight of realities is illustrated with examples. Costs and benefits are reviewed as they relate to positive and negative thinking and positive and negative affect. This paper presents a curvilinear, inverted U-shaped model that suggests that an optimal range of affect is most adaptive and that extremes in either positive or negative affect are less beneficial. “Almost everyone is overconfident—except the people who are depressed, and they tend to be realists.” [32, p. 149] The American way of life is replete with appeals to be encouraging, cheerful, and upbeat. We are told that looking on the bright side is good for us because positive thoughts realize themselves in the form of good health, prosperity, and success [27]. The common view that people should always feel positive about themselves and to think positive has created the perception that negative thinking should be shunned by society. This rejection is dangerous since negative thinking promotes truthful and realistic appraisals: “Truth matters to people, even if it is at the expense of feelings of well-being, self-satisfaction and social adjustment” [69, p.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 100 Ol
    US 2002O102215A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0102215 A1 Klaveness et al. (43) Pub. Date: Aug. 1, 2002 (54) DIAGNOSTIC/THERAPEUTICAGENTS (60) Provisional application No. 60/049.264, filed on Jun. 6, 1997. Provisional application No. 60/049,265, filed (75) Inventors: Jo Klaveness, Oslo (NO); Pal on Jun. 6, 1997. Provisional application No. 60/049, Rongved, Oslo (NO); Anders Hogset, 268, filed on Jun. 7, 1997. Oslo (NO); Helge Tolleshaug, Oslo (NO); Anne Naevestad, Oslo (NO); (30) Foreign Application Priority Data Halldis Hellebust, Oslo (NO); Lars Hoff, Oslo (NO); Alan Cuthbertson, Oct. 28, 1996 (GB)......................................... 9622.366.4 Oslo (NO); Dagfinn Lovhaug, Oslo Oct. 28, 1996 (GB). ... 96223672 (NO); Magne Solbakken, Oslo (NO) Oct. 28, 1996 (GB). 9622368.0 Jan. 15, 1997 (GB). ... 97OO699.3 Correspondence Address: Apr. 24, 1997 (GB). ... 9708265.5 BACON & THOMAS, PLLC Jun. 6, 1997 (GB). ... 9711842.6 4th Floor Jun. 6, 1997 (GB)......................................... 97.11846.7 625 Slaters Lane Alexandria, VA 22314-1176 (US) Publication Classification (73) Assignee: NYCOMED IMAGING AS (51) Int. Cl." .......................... A61K 49/00; A61K 48/00 (52) U.S. Cl. ............................................. 424/9.52; 514/44 (21) Appl. No.: 09/765,614 (22) Filed: Jan. 22, 2001 (57) ABSTRACT Related U.S. Application Data Targetable diagnostic and/or therapeutically active agents, (63) Continuation of application No. 08/960,054, filed on e.g. ultrasound contrast agents, having reporters comprising Oct. 29, 1997, now patented, which is a continuation gas-filled microbubbles stabilized by monolayers of film in-part of application No. 08/958,993, filed on Oct.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]